Xbrane Biopharma AB (OSTO:XBRANE) 5-Year Sharpe Ratio: -0.02 (As of Jun. 24, 2026)


OSTO:XBRANE Xbrane Biopharma AB OSTO:XBRANE
62 GF Score
Price kr10.80
GF Value kr6.26
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Xbrane Biopharma AB 5-Year Sharpe Ratio?

Xbrane Biopharma AB OSTO:XBRANE +0.47% 62 5-Year Sharpe Ratio is -0.02 as of Jun. 24, 2026. GuruFocus rates OSTO:XBRANE with a GF Score™ of 62/100 and a GF Value™ of kr6.26 (Significantly Overvalued). The stock has 5 warning signs investors should review.

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2026-06-24), Xbrane Biopharma AB's 5-Year Sharpe Ratio is -0.02.

Xbrane Biopharma AB  (OSTO:XBRANE) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Xbrane Biopharma AB 5-Year Sharpe Ratio Related Terms

OSTO:XBRANE vs VRTX, REGN, ALNY: 5-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Xbrane Biopharma AB's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xbrane Biopharma AB 5-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's 5-Year Sharpe Ratio falls into.


OSTO:XBRANE
62GF Score
Xbrane Biopharma AB OSTO:XBRANE
5-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xbrane Biopharma AB 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.

Frequently Asked Questions Learn more about 5-Year Sharpe Ratio →
What does a 5-Year Sharpe Ratio of -0.02 mean?
Xbrane Biopharma AB (OSTO:XBRANE) has a 5-Year Sharpe Ratio of -0.02 as of Jun. 24, 2026. 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. View historical data for Xbrane Biopharma AB and its competitors.
Is Xbrane Biopharma AB's 5-Year Sharpe Ratio too high?
Xbrane Biopharma AB's current 5-Year Sharpe Ratio is -0.02. Overall, Xbrane Biopharma AB has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's 5-Year Sharpe Ratio compare to VRTX and REGN?
Xbrane Biopharma AB's 5-Year Sharpe Ratio of -0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Sharpe Ratio for a Biotechnology company?
A good 5-Year Sharpe Ratio depends on the Biotechnology industry context. However, 5-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Sharpe Ratio mean?
A high 5-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. View historical data for Xbrane Biopharma AB and its competitors. Xbrane Biopharma AB's current 5-Year Sharpe Ratio is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Xbrane Biopharma AB (OSTO:XBRANE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.26, compared to a current price of kr10.80 — trading 72.5% above its estimated fair value. The current 5-Year Sharpe Ratio is -0.02. Xbrane Biopharma AB's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Sharpe Ratio calculated?
5-Year Sharpe Ratio is calculated from a company's financial statements. For Xbrane Biopharma AB (OSTO:XBRANE), the current 5-Year Sharpe Ratio is -0.02 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xbrane Biopharma AB (OSTO:XBRANE) Overvalued in 2026?

Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued. The current stock price of kr10.80 is trading 72.5% above its estimated GF Value™ of kr6.26. GuruFocus considers Xbrane Biopharma AB to be Significantly Overvalued.

Key valuation signals for OSTO:XBRANE:

  • 5-Year Sharpe Ratio: -0.02
  • GF Value™: kr6.26 vs. price of kr10.80 (72.5% above fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the OSTO:XBRANE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xbrane Biopharma AB Business Description

Other Exchanges 7XB0:Germany
Address Scheeles vag 5, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
62GF Score

Get the complete analysis for OSTO:XBRANE

5-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.80
Price
kr6.26
GF Value